Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Down |
| Historical APLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -3.31% | |
| Crossed Above 20 DMA | Bullish | -3.41% | |
| Crossed Above 50 DMA | Bullish | -3.41% | |
| Pocket Pivot | Bullish Swing Setup | -3.41% | |
| Outside Day | Range Expansion | -3.41% | |
| Fell Below 20 DMA | Bearish | -0.22% | |
| Fell Below 50 DMA | Bearish | -0.22% | |
| MACD Bearish Signal Line Cross | Bearish | -0.22% | |
| Pocket Pivot | Bullish Swing Setup | -4.29% | |
| 20 DMA Support | Bullish | -3.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below 50 DMA | about 2 hours ago |
| 50 DMA Support | about 2 hours ago |
| Down 3% | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 2 % | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 04/27/2021
Apellis Pharmaceuticals, Inc. Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Eye Organ Systems Inflammatory Disease Inflammatory Diseases Macular Degeneration Related Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Complement System C3 Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Treatment Of Chronic Obstructive Pulmonary Disease Acquired Hemolytic Anemia Intravitreal Administration Pnh Copd Intravitreal Injection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 58.47 |
| 52 Week Low | 25.49 |
| Average Volume | 624,991 |
| 200-Day Moving Average | 41.25 |
| 50-Day Moving Average | 45.19 |
| 20-Day Moving Average | 46.67 |
| 10-Day Moving Average | 47.89 |
| Average True Range | 2.40 |
| ADX | 20.65 |
| +DI | 17.30 |
| -DI | 21.49 |
| Chandelier Exit (Long, 3 ATRs ) | 43.88 |
| Chandelier Exit (Short, 3 ATRs ) | 48.60 |
| Upper Bollinger Band | 50.23 |
| Lower Bollinger Band | 43.11 |
| Percent B (%b) | 0.49 |
| BandWidth | 15.24 |
| MACD Line | 0.66 |
| MACD Signal Line | 0.82 |
| MACD Histogram | -0.1654 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.18 | ||||
| Resistance 3 (R3) | 50.18 | 48.99 | 49.58 | ||
| Resistance 2 (R2) | 48.99 | 48.08 | 48.99 | 49.38 | |
| Resistance 1 (R1) | 47.79 | 47.52 | 48.39 | 47.79 | 49.18 |
| Pivot Point | 46.60 | 46.60 | 46.90 | 46.60 | 46.60 |
| Support 1 (S1) | 45.40 | 45.69 | 46.00 | 45.40 | 44.00 |
| Support 2 (S2) | 44.21 | 45.13 | 44.21 | 43.80 | |
| Support 3 (S3) | 43.01 | 44.21 | 43.60 | ||
| Support 4 (S4) | 43.01 |
